Tenaya Therapeutics Announces Board and Executive Compensation Changes
Ticker: TNYA · Form: 8-K · Filed: Feb 7, 2025 · CIK: 1858848
| Field | Detail |
|---|---|
| Company | Tenaya Therapeutics, Inc. (TNYA) |
| Form Type | 8-K |
| Filed Date | Feb 7, 2025 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $5.25, $1.21, $5.64, $15.19 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, executive-compensation, governance
Related Tickers: TNYA
TL;DR
Tenaya adds a new director and updates exec pay.
AI Summary
On February 6, 2025, Tenaya Therapeutics, Inc. announced changes to its board of directors and executive compensation. Specifically, Dr. Jeffrey W. Chen was appointed as a new director, and the company entered into new employment agreements with certain executive officers, including compensation arrangements.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — The filing reports routine corporate governance changes and executive compensation adjustments, which are common and typically do not represent significant new risks.
Key Players & Entities
- Tenaya Therapeutics, Inc. (company) — Registrant
- Dr. Jeffrey W. Chen (person) — Newly appointed director
- February 06, 2025 (date) — Date of earliest event reported
FAQ
Who was appointed as a new director to Tenaya Therapeutics' board?
Dr. Jeffrey W. Chen was appointed as a new director.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is February 06, 2025.
What are the main topics covered in this 8-K filing?
This filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
What is the principal executive office address for Tenaya Therapeutics, Inc.?
The principal executive office address is 171 Oyster Point Boulevard, Suite 500, South San Francisco, California, 94080.
What is the Commission File Number for Tenaya Therapeutics, Inc.?
The Commission File Number for Tenaya Therapeutics, Inc. is 001-40656.
Filing Stats: 1,282 words · 5 min read · ~4 pages · Grade level 12 · Accepted 2025-02-07 16:41:12
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share TNYA Nasdaq Global Select
- $5.25 — n exercise price per share greater than $5.25 (the "Eligible Options"). The new exe
- $1.21 — price for Mr. Ali's repriced options is $1.21 per share, which was the higher of the
- $5.64 — iously had exercise prices ranging from $5.64 to $15.19 per share. SIGNATURES Pur
- $15.19 — d exercise prices ranging from $5.64 to $15.19 per share. SIGNATURES Pursuant to t
Filing Documents
- tnya-20250206.htm (8-K) — 52KB
- 0000950170-25-016378.txt ( ) — 169KB
- tnya-20250206.xsd (EX-101.SCH) — 25KB
- tnya-20250206_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TENAYA THERAPEUTICS, INC. By: /s/ Jennifer Drimmer Rokovich Jennifer Drimmer Rokovich General Counsel and Secretary Date: February 7, 2025